Comparing Epinephrine, Ephedrine, and Phenylephrine for Hypotension During Anesthesia

Effective management of intraoperative hypotension is essential to maintaining organ perfusion and patient stability, especially in high-risk populations such as obstetric and elderly surgical patients. The vasopressors most commonly used to treat hypotension during anesthesia and surgery include epinephrine, ephedrine, and phenylephrine. Each of these agents has distinct pharmacologic properties that influence their efficacy, onset of action, and cardiovascular effects.

Phenylephrine is a selective α₁-adrenergic agonist widely used to counteract anesthesia-induced hypotension, particularly following spinal or epidural blocks. Its rapid onset and short duration make it ideal for titratable bolus or infusion therapy. By causing potent vasoconstriction, phenylephrine effectively increases systemic vascular resistance and restores arterial pressure. However, its lack of β-adrenergic activity can result in reflex bradycardia and a decrease in cardiac output, which may be undesirable in patients with compromised cardiac function. Even so, phenylephrine remains a first-line agent in many settings, particularly obstetric anesthesia, over ephedrine and epinephrine due to its reliable effects and limited placental transfer.

Ephedrine, in contrast, is a mixed α- and β-adrenergic agonist that also stimulates the release of endogenous norepinephrine. It has a slower onset but produces a longer-lasting response than phenylephrine. Its β-adrenergic effects increase heart rate and cardiac output, making it suitable for patients who exhibit hypotension with bradycardia or low cardiac output. However, ephedrine is associated with tachyphylaxis when used continuously and may cause excessive tachycardia. In obstetric settings, its ability to cross the placenta and stimulate fetal catecholamine release has been linked to transient fetal acidosis, prompting preference for phenylephrine when fetal well-being is a primary concern.

Comparative studies in cesarean section patients have demonstrated that while both ephedrine and phenylephrine are effective in preventing or treating spinal anesthesia-induced hypotension, phenylephrine is associated with better neonatal outcomes, including higher umbilical pH levels. In orthopedic surgery, particularly in elderly patients undergoing hip or lower limb procedures, phenylephrine has been shown to reduce the frequency of hypotensive episodes more effectively than ephedrine. However, some studies suggest that ephedrine provides more stable hemodynamics in elderly patients, with fewer incidents of bradycardia and a lower need for additional vasopressors, highlighting the importance of patient-specific factors in agent selection.

Epinephrine, a potent non-selective adrenergic agonist, is less commonly used for routine hypotension during anesthesia relative to phenylephrine and ephedrine but is beneficial in certain clinical scenarios. It stimulates both α- and β-receptors, producing vasoconstriction along with increased heart rate and cardiac output. Recent trials suggest that epinephrine may be as effective as phenylephrine and norepinephrine in preventing spinal anesthesia-induced hypotension during cesarean delivery. It may reduce the need for rescue vasopressor interventions and support cardiac output more robustly than phenylephrine. However, due to its broad systemic effects, including a higher risk of tachyarrhythmias, its use requires careful consideration and monitoring.

Overall, the choice between epinephrine, ephedrine, and phenylephrine to manage hypotension during anesthesia should be guided by the clinical context and patient-specific variables. Phenylephrine remains the preferred agent in scenarios where vasoconstriction without tachycardia is desirable, such as obstetric anesthesia. Ephedrine offers an advantage in patients with bradycardia or compromised cardiac output but is limited by its potential side effects and impact on fetal physiology. Epinephrine, while promising in select applications, should be reserved for cases where balanced adrenergic support is needed, and its risks can be appropriately managed. Understanding the pharmacologic profiles and clinical implications of epinephrine, ephedrine, and phenylephrine allows anesthesiologists to tailor vasopressor therapy to the individual needs of patients.

References

1. Lin FQ, Qiu MT, Ding XX, Fu SK, Li Q. Ephedrine versus phenylephrine for the management of hypotension during spinal anesthesia for cesarean section: an updated meta-analysis. CNS Neurosci Ther. 2012;18(7):591‑597. doi: 10.1111/j.1755-5949.2012.00345.x.
2. Biricik E, Karacaer F, Ünal İ, Sucu M, Ünlügenç H. The effect of epinephrine for the treatment of spinal-hypotension: comparison with norepinephrine and phenylephrine, clinical trial. Braz J Anesthesiol. 2020;70(5):500‑507. doi: 10.1016/j.bjan.2020.04.017.
3. Abbasivash R, Sane S, Golmohammadi M, et al. Comparing prophylactic effect of phenylephrine and ephedrine on hypotension during spinal anesthesia for hip fracture surgery. Adv Biomed Res. 2016;5:167. doi: 10.4103/2277-9175.190943.
4. Abbasivash R, Sane S. A Comparative Study of Infusion of Ephedrine and Phenylephrine on Hemodynamic Stability After Spinal Anesthesia in Elderly Patients Undergoing Lower Limb Orthopedic Surgeries. Adv Biomed Res. 2016;5:167. PMID: 39445240.